Gilead Sciences (NASDAQ:GILD) Price Target Raised to $129.00

Gilead Sciences (NASDAQ:GILD) had its price objective hoisted by Daiwa Capital Markets from $128.00 to $129.00 in a research report released on Thursday morning,MarketScreener reports. Daiwa Capital Markets currently has an outperform rating on the biopharmaceutical company’s stock.

A number of other research analysts have also issued reports on GILD. Truist Financial reiterated a “buy” rating and set a $145.00 price target (up previously from $127.00) on shares of Gilead Sciences in a research report on Monday, November 3rd. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $135.00 target price on shares of Gilead Sciences in a research report on Friday, October 31st. The Goldman Sachs Group boosted their price target on shares of Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a research report on Friday, October 31st. Finally, UBS Group upped their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research note on Friday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $129.13.

Gilead Sciences Price Performance

NASDAQ GILD opened at $125.02 on Thursday. Gilead Sciences has a 52 week low of $86.08 and a 52 week high of $127.68. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The stock has a market cap of $155.11 billion, a price-to-earnings ratio of 24.90, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32. The company has a 50-day moving average price of $117.44 and a two-hundred day moving average price of $112.83.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Analysts forecast that Gilead Sciences will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be given a dividend of $0.79 per share. The ex-dividend date is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Insider Buying and Selling at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $340,710.00. Following the sale, the insider directly owned 113,193 shares in the company, valued at $12,855,329.01. The trade was a 2.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the sale, the chief executive officer directly owned 581,203 shares of the company’s stock, valued at approximately $69,389,826.17. This represents a 1.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 94,646 shares of company stock worth $11,311,286. 0.27% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Gilead Sciences

Large investors have recently modified their holdings of the stock. One Wealth Advisors LLC boosted its holdings in Gilead Sciences by 34.8% in the second quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock worth $1,016,000 after purchasing an additional 2,364 shares in the last quarter. Ariel Investments LLC boosted its stake in shares of Gilead Sciences by 7.7% during the 1st quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock worth $48,229,000 after acquiring an additional 30,630 shares in the last quarter. Sivik Global Healthcare LLC boosted its position in Gilead Sciences by 25.0% during the second quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company’s stock worth $5,544,000 after purchasing an additional 10,000 shares during the period. Simplify Asset Management Inc. grew its stake in Gilead Sciences by 148.6% in the 2nd quarter. Simplify Asset Management Inc. now owns 52,890 shares of the biopharmaceutical company’s stock valued at $5,864,000 after buying an additional 31,618 shares during the last quarter. Finally, Wealth Management Associates Inc. acquired a new position in Gilead Sciences during the 2nd quarter worth $255,000. 83.67% of the stock is owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.